US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
JP3008208B2
(ja)
*
|
1990-06-01 |
2000-02-14 |
武田薬品工業株式会社 |
新規ハイブリドーマ,その製造法および生理活性物質の製造法
|
GB9022545D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
US6825037B1
(en)
|
1991-02-08 |
2004-11-30 |
University Of Vermont |
Recombinant transferrins, transferrin half-molecules and mutants thereof
|
US5986067A
(en)
*
|
1991-02-08 |
1999-11-16 |
The University Of Vermont And State Agricultural College |
Recombinant transferrins, transferrin half-molecules and mutants thereof
|
WO1992013550A1
(en)
*
|
1991-02-08 |
1992-08-20 |
The University Of Vermont And State Agricultural College |
Recombinant transferrins, transferrin half-molecules and mutants thereof
|
DE4115722A1
(de)
*
|
1991-05-14 |
1992-11-19 |
Boehringer Mannheim Gmbh |
Serumfreies medium zur kultivierung von saeugerzellen
|
WO1993011247A1
(en)
*
|
1991-12-06 |
1993-06-10 |
Genentech, Inc. |
Prohormone convertase transformed cells
|
US6348327B1
(en)
*
|
1991-12-06 |
2002-02-19 |
Genentech, Inc. |
Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
|
WO1993013196A2
(en)
*
|
1991-12-24 |
1993-07-08 |
Genzyme Corporation |
Method for increasing recombinant protein production
|
JPH0763363B2
(ja)
*
|
1991-12-25 |
1995-07-12 |
萩原 義秀 |
融合細胞の取得方法
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US5721121A
(en)
*
|
1995-06-06 |
1998-02-24 |
Genentech, Inc. |
Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
|
US6656466B1
(en)
|
1995-06-06 |
2003-12-02 |
Genetech, Inc. |
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
|
AUPN442295A0
(en)
|
1995-07-26 |
1995-08-17 |
Commonwealth Scientific And Industrial Research Organisation |
Regulated autocrine growth of mammalian cells
|
ATE242809T1
(de)
|
1995-09-08 |
2003-06-15 |
Genentech Inc |
Vegf-verwandtes protein
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
CA2249206A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US7696327B1
(en)
|
1997-10-17 |
2010-04-13 |
Genentech, Inc. |
Antibodies to human Toll homologues
|
US6100076A
(en)
*
|
1997-01-31 |
2000-08-08 |
Genentech, Inc. |
O-fucosyltransferase
|
CA2277266A1
(en)
|
1997-01-31 |
1998-08-06 |
Genentech, Inc. |
O-fucosyltransferase
|
US6136569A
(en)
*
|
1997-02-27 |
2000-10-24 |
Genentech, Inc. |
Method of creating a cDNA library enriched in signal sequences
|
WO1999027098A2
(en)
|
1997-11-21 |
1999-06-03 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US6551799B2
(en)
|
1999-12-07 |
2003-04-22 |
Genentech, Inc. |
Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
|
ATE393222T1
(de)
|
1997-09-18 |
2008-05-15 |
Genentech Inc |
Dcr3 polypeptid, ein tnfr homolog
|
DE69840631D1
(de)
|
1997-10-10 |
2009-04-16 |
Genentech Inc |
Apo-3 ligand
|
ATE409225T1
(de)
|
1997-10-29 |
2008-10-15 |
Genentech Inc |
Durch wnt-1 induzierbare gene
|
ES2313756T3
(es)
|
1997-10-29 |
2009-03-01 |
Genentech, Inc. |
Usos de polipeptido secretado wisp-1 inducido por wnt-1.
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
NZ527898A
(en)
|
1997-12-03 |
2005-01-28 |
Genentech Inc |
PRO347 polypeptides and nucleic acids encoding proteins with homology to cysteine-rich secretory protein-3
|
ZA9811070B
(en)
|
1997-12-08 |
2000-07-03 |
Genentech Inc |
Type I interferons.
|
EP1037995A1
(de)
|
1997-12-08 |
2000-09-27 |
Genentech, Inc. |
Menschliches interferon-epsilon: ein typ 1 interferon
|
US6455250B1
(en)
*
|
1997-12-11 |
2002-09-24 |
The Regents Of The University Of California |
Endonuclease compositions and methods of use
|
JP2002508962A
(ja)
|
1998-01-15 |
2002-03-26 |
ジェネンテク・インコーポレイテッド |
Apo−2リガンド
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
EP1064376B1
(de)
|
1998-03-23 |
2006-03-15 |
Genentech, Inc. |
Gfr-alpha3 und seine verwendungen
|
US6228590B1
(en)
|
1998-03-23 |
2001-05-08 |
Genentech, Inc. |
Method of selection for genes encoding secreted and transmembrane proteins
|
US7026138B1
(en)
|
1998-03-23 |
2006-04-11 |
Genentech, Inc. |
Polynucleotides encoding GFRα3
|
EP3112468A1
(de)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17-homologe polypeptide und therapeutische verwendung davon
|
EP1865061A3
(de)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
IL138930A0
(en)
|
1998-05-15 |
2001-11-25 |
Genentech Inc |
Il-17 homologies polypeptides and therapeutic uses thereof
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
CA2344467C
(en)
|
1998-09-22 |
2011-01-25 |
Genentech, Inc. |
Ucp4
|
US7399751B2
(en)
*
|
1999-11-04 |
2008-07-15 |
Sertoli Technologies, Inc. |
Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
|
WO2000032624A2
(en)
|
1998-11-30 |
2000-06-08 |
Genentech, Inc. |
Uncoupling protein 5 - ucp5
|
US7342102B2
(en)
|
1998-11-30 |
2008-03-11 |
Genentech, Inc. |
Uncoupling protein 5 (UCP5)
|
EP1484338B1
(de)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums
|
EP1141299A2
(de)
|
1998-12-23 |
2001-10-10 |
Genentech, Inc. |
Il-1 verwandte polypeptide
|
JP4716578B2
(ja)
|
1999-04-12 |
2011-07-06 |
ジェネンテック, インコーポレイテッド |
腫瘍壊死因子相同体及びそれをコードする核酸
|
EP1953173B1
(de)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
NZ529329A
(en)
|
1999-08-25 |
2005-06-24 |
Immunex Corp |
Compositions and methods for improved cell culture
|
NZ531141A
(en)
|
1999-10-20 |
2005-07-29 |
Genentech Inc |
Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
|
CA2490853A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7226591B2
(en)
|
2000-05-22 |
2007-06-05 |
Genentech, Inc. |
Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
|
EP1897947B1
(de)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
EP1757701A1
(de)
|
1999-12-24 |
2007-02-28 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
|
EP2180054A1
(de)
|
1999-12-24 |
2010-04-28 |
Genentech, Inc. |
Verfahren und Zusammenstellungen zur Verlängerung der Entsorgungshalbzeiten von bioaktiven Verbindungen
|
CN1425066B
(zh)
|
2000-01-13 |
2010-05-26 |
杰南技术公司 |
新的stra6多肽
|
ATE329610T1
(de)
|
2000-02-16 |
2006-07-15 |
Genentech Inc |
Anti-april antikörper und hybridomazellen
|
IL151853A0
(en)
|
2000-04-11 |
2003-04-10 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(de)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(de)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
ES2361824T3
(es)
|
2000-12-20 |
2011-06-22 |
F. Hoffmann-La Roche Ag |
Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
JP2004528309A
(ja)
*
|
2001-03-23 |
2004-09-16 |
ナプロ バイオセラピューティクス,インコーポレイテッド |
癌治療用分子複合体
|
US20040161817A1
(en)
*
|
2001-06-04 |
2004-08-19 |
Corixa Corporation |
Compositions and methods for high-level, large-scale production of recombinant proteins
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
MXPA03011985A
(es)
|
2001-06-20 |
2004-03-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
US7060278B2
(en)
|
2001-08-29 |
2006-06-13 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US7164002B2
(en)
|
2002-02-06 |
2007-01-16 |
Genentech, Inc. |
FVIIa antagonists
|
WO2003072035A2
(en)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
CA2489588A1
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP2277532A1
(de)
|
2002-09-11 |
2011-01-26 |
Genentech, Inc. |
Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
|
WO2004024072A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP1562587A4
(de)
|
2002-09-11 |
2006-07-19 |
Genentech Inc |
Neue zusammensetzungen und verfahren zur behandlung von immunkrankheiten
|
CA2498274A1
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro7
|
EP1585482A4
(de)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
Neue zusammensetzungen und verfahren zur behandlung von psoriasis
|
EP1576137A4
(de)
|
2002-10-29 |
2010-06-30 |
Genentech Inc |
Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
|
CA2503748A1
(en)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7285269B2
(en)
*
|
2002-12-02 |
2007-10-23 |
Amgen Fremont, Inc. |
Antibodies directed to tumor necrosis factor
|
CN102225194B
(zh)
|
2003-03-12 |
2014-07-16 |
健泰科生物技术公司 |
Bv8和/或EG-VEGF促进造血的用途
|
WO2004091658A1
(en)
|
2003-04-04 |
2004-10-28 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
US20050118145A1
(en)
*
|
2003-07-03 |
2005-06-02 |
Jannette Dufour |
Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP2161283B1
(de)
|
2003-11-17 |
2014-06-04 |
Genentech, Inc. |
Zusammensetzungen, die Antikörper gegen CD79b enthalten, die an Wachstumshemmer oder an zytotoxische Subtanzen gekoppelt sind und Verfahren zur Behandlung von Tumoren hämatopoetischen Ursprungs
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
BRPI0618178A2
(pt)
*
|
2005-11-02 |
2011-08-23 |
Wyeth Corp |
métodos para adaptação de células de mamìferos
|
US20070231895A1
(en)
*
|
2005-11-02 |
2007-10-04 |
Lee Gene W |
Methods for adapting mammalian cells
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
CA2647277A1
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007127936A2
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
CA2659990C
(en)
|
2006-08-04 |
2016-03-22 |
Prolong Pharmaceuticals, Inc. |
Polyethylene glycol erythropoietin conjugates
|
EP2066174B1
(de)
|
2006-09-12 |
2017-11-08 |
Beth Israel Deaconess Medical Center, Inc. |
Zusammensetzungen mit alpha-1-antitrypsin und verwendungsverfahren dafür
|
SG176476A1
(en)
|
2006-11-02 |
2011-12-29 |
Daniel J Capon |
Hybrid immunoglobulins with moving parts
|
US20120093796A1
(en)
|
2007-03-22 |
2012-04-19 |
Industry Academic Cooperation Foundation, The Catholic University Of Korea |
Novel use of ec-sod and method for preparing thereof
|
US9089564B2
(en)
|
2007-03-22 |
2015-07-28 |
The Catholic University of Korea Industry-Academic Cooperatior |
Use of EC-SOD for treating angiogenesis-mediated eye diseases
|
EP4335863A3
(de)
|
2007-07-09 |
2024-07-24 |
Genentech, Inc. |
Verhinderung der disulfidbindungsreduktion während der rekombinanten herstellung von polypeptiden
|
CA2697519C
(en)
|
2007-09-05 |
2018-11-20 |
Genentech, Inc. |
Biologically active c-terminal arginine-containing peptides
|
EP2235063B1
(de)
|
2007-12-28 |
2015-09-02 |
Genentech, Inc. |
Anti-hedgehog-antikörper
|
CA2720610C
(en)
|
2008-04-07 |
2016-08-23 |
Bayer Healthcare Llc |
Methods of recombinant production of glycoproteins
|
US9511085B2
(en)
|
2008-08-18 |
2016-12-06 |
Medicinal Bioconvergence Research Center |
Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
|
MX347112B
(es)
|
2008-09-15 |
2017-04-12 |
Genentech Inc |
Composiciones y metodos para regular osmolaridad celular.
|
EP2351575B1
(de)
|
2008-10-10 |
2016-12-14 |
SNU R & DB Foundation |
Grs in der verwendung zur behandlung von krebs
|
KR20220047668A
(ko)
|
2008-12-09 |
2022-04-18 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
LT2464725T
(lt)
|
2009-08-11 |
2020-06-10 |
F. Hoffmann-La Roche Ag |
Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
|
AU2010297530B2
(en)
|
2009-09-23 |
2013-12-19 |
Ratiopharm Gmbh |
Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
EA030418B1
(ru)
|
2010-07-12 |
2018-08-31 |
ЭйТИР ФАРМА, ИНК. |
ТЕРАПЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ, ПОЛИПЕПТИД АМИНОАЦИЛ-тРНК-СИНТЕТАЗЫ (AARS)
|
EP2603525A1
(de)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antikörper gegen il-1beta und il-18 zur behandlung von krankheiten
|
WO2012075238A1
(en)
|
2010-12-02 |
2012-06-07 |
Genentech, Inc. |
Novel receptor-ligand interaction and uses thereof
|
WO2012088383A2
(en)
|
2010-12-23 |
2012-06-28 |
Genentech, Inc. |
PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
|
CN102586190B
(zh)
*
|
2011-01-11 |
2014-01-01 |
北京华安科创生物技术有限公司 |
高效表达重组人神经生长因子的cho细胞株及其构建方法
|
WO2013077534A1
(en)
|
2011-11-23 |
2013-05-30 |
Cell Biotech Co., Ltd. |
Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same
|
RU2639564C2
(ru)
|
2011-12-16 |
2017-12-21 |
Браскем С.А. |
Модифицированные микроорганизмы и способы получения бутадиена с их применением
|
DK2814514T3
(en)
|
2012-02-16 |
2017-12-18 |
Atyr Pharma Inc |
Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
DK2841087T3
(da)
|
2012-04-27 |
2017-11-20 |
Us Health |
Vaskulær endothel-vækstfaktor-antagonister og fremgangsmåder til anvendelse deraf
|
EP2749569A1
(de)
*
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variante des BPIFB4-Proteins
|
DK2968495T3
(da)
|
2013-03-15 |
2019-10-14 |
Daniel J Capon |
Hybrid immunoglobulin indeholdende en ikke-peptid-bro
|
ES2665596T3
(es)
|
2013-03-15 |
2018-04-26 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Uso de compuestos intermedios de ácido tricarboxílico (ATC) para controlar la generación de amoníaco en cultivo celular
|
CN105121628B
(zh)
|
2013-03-15 |
2020-03-24 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
ES2708565T3
(es)
|
2013-03-15 |
2019-04-10 |
Atyr Pharma Inc |
Conjugados de Fc-histidil-ARNt sintetasa
|
EP2829608A1
(de)
|
2013-07-23 |
2015-01-28 |
Universität Bielefeld |
Verfahren zur Herstellung von rekombinanten Proteinen in Säugerzellen
|
BR112016006321B1
(pt)
|
2013-09-23 |
2022-11-16 |
Braskem S.A |
Enzima engenheirada tendo especificidade de substrato aceto acetil-coa e atividade aceto acetil-coa específica de hidrolase, micro-organismo modificado, e, processo de produção de um ou mais produtos a partir de uma fonte de carbono fermentável
|
HUE065394T2
(hu)
|
2013-11-15 |
2024-05-28 |
Hoffmann La Roche |
Vírusok inaktiválására szolgáló eljárások környezetbarát detergensek alkalmazásával
|
SI3110961T1
(sl)
|
2014-02-27 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina
|
PT3116486T
(pt)
|
2014-03-14 |
2020-03-12 |
Biomolecular Holdings Llc |
Imunoglobulina híbrida que contém uma ligação não peptídica
|
MX2016013223A
(es)
|
2014-04-10 |
2017-04-27 |
Bayer Healthcare Llc |
Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular.
|
KR101619863B1
(ko)
|
2014-05-23 |
2016-05-24 |
주식회사 제노포커스 |
신규 베타-갈락토시다아제
|
US11345908B2
(en)
|
2014-05-30 |
2022-05-31 |
Braskem S.A. |
Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
|
KR101730035B1
(ko)
|
2015-03-20 |
2017-04-26 |
한국과학기술원 |
L-아스파르트산 유도체를 생산하는 변이미생물 및 이를 이용한 l-아스파르트산 유도체의 제조방법
|
KR101839595B1
(ko)
|
2015-04-13 |
2018-04-26 |
한국과학기술원 |
락탐의 제조방법
|
KR20160141123A
(ko)
|
2015-05-28 |
2016-12-08 |
주식회사 제노포커스 |
고당전이 활성의 베타-갈락토시다제 변이체 및 그 용도
|
KR101702906B1
(ko)
|
2015-07-15 |
2017-02-22 |
주식회사 제노포커스 |
신규 알파-1,3-글루카나제
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
KR101756338B1
(ko)
|
2016-01-15 |
2017-07-10 |
고려대학교 산학협력단 |
L-시스테인 생산용 변이미생물 및 이를 이용한 l-시스테인의 제조방법
|
EP3494131A4
(de)
|
2016-08-02 |
2020-04-15 |
Vaccinex, Inc. |
Verbesserte verfahren zur herstellung von polynukleotidbibliotheken in vaccinia virus/eukaryotischen zellen
|
EP3339444A1
(de)
|
2016-12-20 |
2018-06-27 |
Mabxience Research, S.L. |
Verfahren zur herstellung eines glycoproteins mit erhöhtem prozentualem anteil an afucosylierten glycanen
|
CN110536694A
(zh)
|
2017-04-20 |
2019-12-03 |
Atyr 医药公司 |
用于治疗肺部炎症的组合物和方法
|
AU2019245243A1
(en)
|
2018-03-29 |
2020-09-03 |
Genentech, Inc |
Modulating lactogenic activity in mammalian cells
|
KR102658830B1
(ko)
|
2018-08-02 |
2024-04-19 |
에스케이이노베이션 주식회사 |
내열성 탄산무수화효소 변이체 및 이를 포함하는 이산화탄소 포집용 조성물
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
BR112021010374A2
(pt)
|
2018-12-21 |
2021-08-24 |
23Andme, Inc. |
Anticorpos anti-il-36 e métodos de uso dos mesmos
|
KR102346050B1
(ko)
|
2019-01-25 |
2022-01-03 |
주식회사 네오믹스 |
미백 활성을 갖는 신규 폴리펩타이드 및 이의 용도
|
WO2021209512A1
(en)
|
2020-04-15 |
2021-10-21 |
Genentech, Inc. |
Method for medium treatment before inoculation
|
KR20230018425A
(ko)
|
2020-05-29 |
2023-02-07 |
23앤드미 인코포레이티드 |
항-cd200r1 항체 및 이의 사용 방법
|
US20230235040A1
(en)
|
2020-06-22 |
2023-07-27 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
MX2022016453A
(es)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Lineas celulares resistentes a la apoptosis.
|
PE20230983A1
(es)
|
2020-08-07 |
2023-06-21 |
Genentech Inc |
Proteinas de fusion del ligando para flt3 y metodos de uso
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
KR102613962B1
(ko)
|
2020-09-07 |
2023-12-18 |
주식회사 지아이셀 |
코로나바이러스 유래 수용체 결합 도메인 및 뉴클레오캡시드 단백질을 포함하는 융합단백질 및 이의 용도
|
KR20220059399A
(ko)
|
2020-11-02 |
2022-05-10 |
한국과학기술원 |
소수성 물질의 생산능이 향상된 재조합 미생물 및 이의 제조를 위한 세포막 엔지니어링 방법
|
CA3200954A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
KR102661294B1
(ko)
|
2020-12-24 |
2024-04-30 |
한국과학기술원 |
글루타르산 수송체 유전자가 도입된 재조합 미생물 및 이를 이용한 글루타르산의 제조방법
|
EP4326855A1
(de)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modifizierte säugerzellen
|
WO2022256613A1
(en)
|
2021-06-04 |
2022-12-08 |
Genentech, Inc. |
Identification and quantitation of residual host cell proteins in protein samples
|
EP4402469A1
(de)
|
2021-09-15 |
2024-07-24 |
Genentech, Inc. |
Metabolomische analyse
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|